World's Best Scientists 2026 revealed!
Stewart A. Factor

Stewart A. Factor

D-Index & Metrics

Medicine

D-Index
89
Citations
31529
World Ranking
12618
National Ranking
6454

Overview

Stewart A. Factor is affiliated with Emory University in the United States and has an extensive publication record in the field of Medicine, with a particular focus on Neurology. Their work spans multiple subfields including Neurology, Psychiatry and Mental Health, Cellular and Molecular Neuroscience, Physical Therapy, Sports Therapy and Rehabilitation, and Molecular Biology.

The main research topics addressed by Stewart A. Factor include:

  • Parkinson's Disease Mechanisms and Treatments
  • Neurological disorders and treatments
  • Botulinum Toxin and Related Neurological Disorders
  • Genetic Neurodegenerative Diseases
  • Balance, Gait, and Falls Prevention
  • Cerebral Palsy and Movement Disorders
  • Schizophrenia research and treatment

Among the frequent publication venues are:

  • Neurology (18 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (10 publications)
  • CNS Spectrums (9 publications)
  • Movement Disorders Clinical Practice (7 publications)
  • Parkinsonism & Related Disorders (6 publications)

Stewart A. Factor has collaborated frequently with the following co-authors:

  • J. Lucas McKay (26 co-authored publications)
  • Robert A. Hauser (22 co-authored publications)
  • Christine D. Esper (18 co-authored publications)
  • Joohi Jimenez-Shahed (17 co-authored publications)
  • Karen E. Anderson (17 co-authored publications)

Selected recent papers:

  • Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer's disease, 2020, Science Advances
  • Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens, 2020, npj Parkinson's Disease
  • Dystonia and Tremor, 2020, Neurology
  • Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial, 2023, The Lancet Neurology
  • Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial, 2022, Nature Medicine

Best Publications

  • The Parkinson Progression Marker Initiative (PPMI)

    Kenneth Marek;Danna Jennings;Shirley Lasch;Andrew Siderowf

  • Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease

    Taye H. Hamza;Cyrus P. Zabetian;Cyrus P. Zabetian;Albert Tenesa;Alain Laederach

  • Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome

    Erin M. Hill-Burns;Justine W. Debelius;James T. Morton;William T. Wissemann

  • Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

    Robert G Holloway;Ira Shoulson;Stanley Fahn;Karl Kieburtz

  • Practice Parameter: Treatment of Parkinson Disease With Motor Fluctuations and Dyskinesia (An Evidence-Based Review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

    R. Pahwa;S. A. Factor;K. E. Lyons;William G. Ondo

  • The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort

    Kenneth Marek;Sohini Chowdhury;Andrew Siderowf;Shirley Lasch

  • Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database.

    Christina M. Lill;Johannes T. Roehr;Johannes T. Roehr;Matthew B. McQueen;Fotini K. Kavvoura;Fotini K. Kavvoura;Fotini K. Kavvoura

  • Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group

    Bernard Ravina;Karen Marder;Hubert H. Fernandez;Joseph H. Friedman

  • Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.

    A. Brashear;M. F. Lew;D. D. Dykstra;C. L. Comella

  • Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease

    Ju-Hee Kang;Ju-Hee Kang;David J. Irwin;Alice S. Chen-Plotkin;Andrew Siderowf

  • A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

    I. H. Richard;M. P. McDermott;R. Kurlan;J. M. Lyness

  • Ropinirole 24-hour prolonged release: Randomized, controlled study in advanced Parkinson disease

    R. Pahwa;M. A. Stacy;S. A. Factor;K. E. Lyons

  • A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia.

    Robert A. Hauser;Jeffrey Friedlander;Theresa A. Zesiewicz;Charles H. Adler

  • Mutations in GNAL cause primary torsion dystonia.

    Tania Fuchs;Rachel Saunders-Pullman;Rachel Saunders-Pullman;Ikuo Masuho;Marta San Luciano

  • Meta-analysis of Parkinson's Disease: Identification of a Novel Locus, RIT2

    Nathan Pankratz;Gary W. Beecham;Anita L. Destefano;Ted M. Dawson

  • Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial.

    C. Warren Olanow;Raymond T. Bartus;Tiffany L. Baumann;Stewart Factor

  • Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia

    Mark F. Lew;B. T. Adornato;D. D. Duane;D. D. Dykstra

  • Occupation and Risk of Parkinsonism: A Multicenter Case-Control Study

    Caroline M. Tanner;G. Webster Ross;Sarah A. Jewell;Robert A. Hauser

  • Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease

    Joseph H. Friedman;Stewart A. Factor

  • Levodopa in the treatment of Parkinson's disease: a consensus meeting.

    Y. Agid;E. Ahlskog;A. Albanese;D. Calne

Frequent Co-Authors

Cyrus P. Zabetian
Cyrus P. Zabetian University of Washington
Haydeh Payami
Haydeh Payami University of Alabama at Birmingham
Robert A. Hauser
Robert A. Hauser University of South Florida
Joseph Jankovic
Joseph Jankovic Baylor College of Medicine
Hubert H. Fernandez
Hubert H. Fernandez Cleveland Clinic
Ali Samii
Ali Samii University of Washington
Felicia C. Goldstein
Felicia C. Goldstein Emory University
Caroline M. Tanner
Caroline M. Tanner University of California, San Francisco
Hyder A. Jinnah
Hyder A. Jinnah Emory University
John G. Nutt
John G. Nutt Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Whether you’re considering a future in medicine or want to explore related fields, a variety of online degree options are available for those seeking flexibility and affordability. Pursuing a healthcare degree online can open pathways to management, clinical leadership, pharmacy, or health information careers.

For those interested in leadership roles within healthcare organizations, consider exploring some of the cheapest mha programs online. These programs provide essential skills in administration and policy while keeping costs manageable.

Aspiring advanced practice nurses can find cheap online dnp programs that lead to the highest clinical degree in nursing, often with flexible learning schedules.

If pharmacy interests you, a pharmacy degree online offers accredited pathways to become a Doctor of Pharmacy—balancing career advancement with distance learning.

Lastly, the rise of digital health records and data analytics has made an online mhi valuable for those aiming to manage health information systems.

Explore these programs to determine which pathway best fits your interests and goals in the evolving healthcare landscape.

Best Scientists Citing Stewart A. Factor

Trending Scientists

Recently Published Articles